Related Experiment Videos
Complete remissions in non small cell lung cancer.
Medical Oncology and Tumor Pharmacotherapy
|January 1, 1985
Summary
This study on non-small cell lung cancer found that chemotherapy regimens including cisplatin, etoposide, and vindesine led to prolonged survival in some complete responders. Further research is needed to optimize treatment strategies.
Area of Science:
- Oncology
- Medical Research
Background:
- Non-small cell lung cancer (NSCLC) is a significant global health concern.
- Chemotherapy remains a cornerstone in NSCLC treatment, with various combination regimens explored.
Purpose of the Study:
- To evaluate the efficacy of cisplatin and etoposide versus cisplatin, etoposide, and vindesine in treating NSCLC patients.
- To assess response rates and survival outcomes in patients receiving these chemotherapy regimens.
Main Methods:
- A study involving 241 patients diagnosed with non-small cell bronchogenic cancer.
- Patients were treated with either cisplatin and etoposide or a combination of cisplatin, etoposide, and vindesine.
Main Results:
- A total of 11 patients (4.5%) achieved a complete response to the treatment.
- A notable proportion of these complete responders experienced prolonged survival, indicating potential long-term benefits.
Conclusions:
- Combination chemotherapy, particularly regimens including vindesine, may offer survival advantages for a subset of NSCLC patients.
- The findings highlight the importance of individualized treatment approaches and further investigation into predictive markers for treatment response.